Effect estimates for complete clearance at the end of treatment (selected comparisons) and recurrence vs podophyllotoxin 0.5% solution
| Outcome | Primary analysis | Sensitivity analysis | ||
| OR (95% credible interval) | SUCRA | OR (95% credible interval) | SUCRA | |
| Complete clearance at end of treatment (OR <1 favours podophyllotoxin 0.5% solution) | ||||
| Podophyllotoxin 0.5% solution | N/A | 79.7% | N/A | 65.0% |
| Imiquimod 5% cream | 0.07 (0.001 to 0.36) | 24.1% | 0.20 (0.02 to 0.75) | 26.3% |
| TCAA 80%–90% | 2.61 (0.001 to 10.61) | 44.5% | 2.68 (0.01 to 15.32) | 46.9% |
| Cryotherapy | 0.78 (0.005 to 4.52) | 49.2% | 0.92 (0.06 to 4.03) | 51.7% |
| Cryotherapy plus podophyllotoxin 0.15% cream | 7.16 (0.002 to 23.97) | 60.1% | 5.80 (0.02 to 33.74) | 61.2% |
| Surgical excision | 2.75 (0.01 to 16.31) | 64.2% | 7.89 (0.03 to 47.47) | 64.5% |
| CO2 laser therapy | 95.41 (0.04 to 376.50) | 92.3% | 91.97 (0.30 to 560.3) | 92.0% |
| Podophyllotoxin 0.15% cream | – | 0.68 (0.05 to 3.04) | 45.7% | |
| Polyphenon E 10% ointment | – | 0.03 (<0.001 to 0.18) | 8.0% | |
| Electrotherapy | – | 13.51 (0.46 to 76.11) | 86.8% | |
| Cidofovir | – | 13.72 (0.04 to 81.66) | 65.3% | |
| Recurrence (OR >1 favours podophyllotoxin 0.5% solution) | ||||
| Imiquimod 5% cream | 1.76 (0.05 to 9.00) | 54.5% | N/A | |
| Cryotherapy | 4.42 (0.06 to 22.20) | 33.5% | N/A | |
| Surgical excision | 0.75 (0.007 to 3.67) | 90.3% | N/A | |
CO2, carbon dioxide; N/A, not applicable; OR, odds ratio; SUCRA, surface under the cumulative ranking; TCAA, trichloroacetic acid.